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Background: Older individuals often have a reduced immune response to influenza vaccination, which might be
improved by administering a higher vaccine dose. We compared the immune response to two single doses of
the AS03A-adjuvanted H5N1 pandemic vaccine (3.75 μg hemagglutinin of A/Vietnam/1194/2004) with that of two
double vaccine doses (7.5 μg hemagglutinin) in adults aged ≥61 years. Here we report the 2-year persistence of the
humoral and cellular immune response.
Methods: In this phase II, open-label study, healthy participants aged 61 to 88 years (median 68 years) were randomised
(3:1:3:1) to receive two single doses of the AS03A-adjuvanted vaccine (1xH5N1-AS) or the non-adjuvanted vaccine
(1xH5N1), or two double doses of the AS03A-adjuvanted vaccine (2xH5N1-AS) or the non-adjuvanted vaccine (2xH5N1),
21 days apart. Serum haemagglutination inhibition antibodies and cellular immune responses against A/Vietnam/1194/
2004 were measured in all groups at months 12 and 24; neutralising antibodies were assessed in a subset of the
adjuvanted groups. Serious adverse events and adverse events of specific interest were recorded.
Results: At month 24, haemagglutination inhibition antibody seroprotection rates were 37.2% (95% CI 27.0% to 48.3%)
for 1xH5N1-AS, 30.9% (95% CI 21.1% to 42.1%) for 2xH5N1-AS, 16.2% (95% CI 6.2% to 32.0%) for 1xH5N1, and 8.3% (95%
CI 1.0% to 27.0%) for 2xH5N1. Haemagglutination inhibition antibody geometric mean titres were 17.6 (95% CI 13.7 to
22.5) for 1xH5N1-AS, 18.4 (95% CI 14.2 to 23.8) for 2xH5N1-AS, 12.3 (95% CI 8.9 to 16.9) for 1xH5N1 and 9.8 (95% CI 6.7 to
14.4) for 2xH5N1. The median frequency of antigen-specific CD4+ T cells per 106 T cells (25th quartile; 75th quartile) was
852 (482; 1477) for 1xH5N1-AS, 1147 (662; 1698) for 2xH5N1-AS, 556 (343; 749) for 1x-H5N1 and 673 (465; 1497) for
2xH5N1. Neutralising antibody geometric mean titres were 391.0 (95% CI 295.5 to 517.5) in the 1xH5N1-AS group and
382.8 (95% CI 317.4 to 461.6) in the 2xH5N1-AS group.
Conclusions: Antibody levels declined substantially in all groups. Seroprotection rates, geometric mean titres for
haemagglutination inhibition antibodies, and CD4+ T-cell responses tended to be higher in the AS03A-adjuvanted groups.
There was no clear benefit, in terms of long-term persistence of the immune response, of doubling the dose of the
adjuvanted vaccine. No safety concern was observed up to 24 months post-primary vaccination.
Trial registration: NCT00397215 (7 November 2006).
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Outbreaks of avian influenza H5N1 viruses emerged in
1997 and remain a considerable threat. A key strategy
for pandemic preparedness involves the development
of a pre-pandemic vaccine to prime the immune sys-
tem against H5 variants [1]. Partial cross-protection
may have a considerable impact on infection rates
during early pandemic stages [2,3]. The induction of
long-lasting immune memory by a pre-pandemic vac-
cine may allow for sufficient protection to be induced
by just a single booster vaccine [1,4,5].
An H5N1 pre-pandemic AS03A-adjuvanted vaccine
based on the A/Vietnam/1194/2004 clade 1 strain is li-
censed for prophylaxis of influenza in an officially declared
pandemic situation, with a schedule of two injections
administered 3 weeks apart, from the age of 18 years on-
wards [6]. This vaccine has been shown to induce a cross-
reactive immune response against drifted clade 2 H5N1
strains [7-11].
In adults aged 18 to 60 years, a formulation of this adju-
vanted H5N1 vaccine containing 3.75 μg hemagglutinin
was sufficient to meet all US Center for Biologics Evalu-
ation and Research and European Committee for Human
Medicinal Products (CHMP) immunologic licensure cri-
teria [7]. Older persons often experience a reduced im-
mune response to influenza vaccination, which is thought
to be, at least partially, due to immunosenescence [12]. It
is therefore anticipated that these individuals may need
higher doses to enhance their immune response after
vaccination.
We previously reported on the immunogenicity and
safety of a single (3.75 μg) or double (7.50 μg) dose of
the AS03A-adjuvanted H5N1 pandemic vaccine in indi-
viduals aged ≥61 years in a randomised, open-label study
(NCT00397215) conducted in Belgium and Italy [13].
Both the single and the double dose regimens were
found to be well tolerated and highly immunogenic
when administered as a two-dose schedule 21 days apart.
Although a double dose elicited a stronger immune re-
sponse, the single dose was sufficient to meet all CHMP
criteria for influenza vaccines in the elderly population.
The immune response to both the single and double
adjuvanted dose remained high after 6 months [13].
The current manuscript presents follow-up data
from the population in Belgium on the persistence of
the humoral and cellular immune responses up to
2 years after the first vaccination with the H5N1 vac-
cine. We assessed the persistence of the immune re-
sponse against the vaccine-homologous A/Vietnam/
1194/2004 strain, as well as against the heterologous
A/Indonesia/05/2005 strain. Safety data, in terms of
serious adverse events (SAE) and adverse events of
specific interest (AESI) up to 24 months after the first
vaccination, are also presented.Methods
Study vaccines
The H5N1 inactivated, split-virion recombinant vaccine
was manufactured by GSK Vaccines (Dresden, Germany),
as described elsewhere [7,8]. The vaccine contained
3.75 μg hemagglutinin of the A/Vietnam/1194/2004-like
NIBRG-14 clade 1 strain (National Institute for Bio-
logical Standards and Control). The adjuvanted vac-
cine (Prepandrix™, GSK Vaccines) contained AS03A,
an oil-in-water emulsion-based adjuvant system con-
taining 11.86 mg tocopherol [7]. The vaccines (0.5 ml
per single dose) were administered intramuscularly
into the deltoid region of the non-dominant arm for
the single dose and into the deltoid region of each arm
for the double dose.Study design and participants
The study took place between November 2006 and
September 2009. The first part of this phase II, rando-
mised, open-label study (NCT00397215) was conducted
in multiple centres in Italy and Belgium and has been re-
ported previously [13]. The long-term persistence of im-
mune response and safety data at month 12 and month
24, reported here, were only evaluated for participants in
Belgium, as specified in the amended study protocol; the
cohort of subjects recruited in Italy was too small to
warrant follow-up.
Male and female participants aged ≥61 years, who
were in good health or who had well controlled under-
lying disease, were randomised (3:1:3:1) to one of four
vaccine study groups to receive either two single doses
of the AS03A-adjuvanted vaccine (1xH5N1-AS), two
single doses of the non-adjuvanted vaccine (1xH5N1),
two double doses of the AS03A-adjuvanted vaccine
(2xH5N1-AS), or two double doses of the non-adjuvanted
vaccine (2xH5N1). The vaccines were administered ac-
cording to a two-dose schedule (day 0 and day 21). The
majority of participants had not received an influenza vac-
cine for the 2006 to 2007 season and were vaccinated with
Fluarix™ Northern hemisphere 2006/2007 (GSK Vaccines)
3 weeks before administration of the H5N1 vaccine.
Participants in each group were stratified by age group
(61 to 65, 66 to 70, and >70 years) to ensure equal enrol-
ment in each age stratum. Treatment allocation at the
investigator sites was performed using a central random-
isation system.
The study was conducted in accordance with the
Declaration of Helsinki and the International Confer-
ence on Harmonisation Good Clinical Practice guide-
lines. The protocol was approved by the independent
ethics committee or institutional review board of each
study centre (listed in Additional file 1). Written in-
formed consent was obtained from each participant.
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The primary objectives of this study were to evaluate the
immunogenicity of the H5N1 vaccine 21 days after both
the first and the second dose, as reported previously
[13], and to assess persistence of the immune response
for up to 2 years (reported in the current manuscript).
Secondary objectives included safety assessment and
evaluation of the cell-mediated immune response in
terms of T helper 1-specific activation marker expres-
sion after in vitro re-stimulation of influenza-specific
CD4+ and CD8+ T cells.
Immunogenicity evaluation
We assessed the immunogenicity against two influenza
strains: the vaccine-homologous A/Vietnam/1194/2004
strain and the vaccine-heterologous A/Indonesia/05/2005
strain.
Blood samples were taken at 12 and 24 months after
the first vaccination. A haemagglutination inhibition
(HI) assay was used to measure HI antibody titres in
serially-diluted serum samples (initial dilution of 1:10,
followed by two-fold serial dilution series using standard
techniques [14]). The reported serum titre was the geo-
metric mean of duplicate testing data. The assay cut-off
was 10 (the reciprocal of the initial serum dilution); anti-
body titres below the cut-off were given an arbitrary
value of half the cut-off for geometric mean titre (GMT)
calculation. The following parameters were determined
with 95% CIs at month 12 and month 24: H5N1 anti-
body GMTs, seroconversion rates (SCRs; defined as the
percentage of participants with either a pre-vaccination
titre <1:10 and a post-vaccination titre ≥1:40, or a pre-
vaccination titre ≥1:10 and a ≥4-fold increase in post-
vaccination titre) and seroprotection rate (SPR; defined
as the percentage of participants with an HI titre ≥1:40).
The microneutralisation assay was performed as de-
scribed previously [13]. Each serum sample was tested in
triplicate. The 50% neutralisation titre of the serum was
calculated according to the method of Reed and Muench
[15]. The assay cut-off was 28; antibody titres below the
cut-off were given an arbitrary value of half the cut-off
for GMT calculation. Neutralising antibodies were evalu-
ated in a subset of participants in the AS03A-adjuvanted
vaccine groups at months 12 and 24 using the following
parameters with their 95% CIs: H5N1 antibody GMTs
and SCRs (defined as the percentage of vaccinees with
a ≥4-fold increase in neutralising antibody titre at post-
vaccination).
The cell-mediated immune response was assessed as
described previously [13], and was only evaluated for the
A/Vietnam/1194/2004 strain. Results were expressed as
frequency of CD4+ or CD8+ T cells responding to the
antigen and expressing at least two markers (CD40L,
interferon-γ, interleukin-2 or tumour necrosis factor-α)per million CD4+ or CD8+ T cells in total. Response was
measured at month 12 and month 24.
Safety evaluation
We evaluated the occurrence of SAEs and AESIs (includ-
ing autoimmune diseases and other immune-mediated in-
flammatory disorders) during the entire study. SAEs were
defined as any medical occurrence that resulted in death,
was a life-threatening event, resulted in disability or incap-
acity, or required hospitalisation or prolonged existing
hospitalisation. Reactogenicity data have been reported
previously [13].
Statistical analysis
Determination of the target sample size has been de-
scribed previously [13].
Analysis of humoral immunogenicity was performed
on the month 24 according-to-protocol (ATP) persist-
ence cohort, including all participants enrolled in
Belgium who met all eligibility criteria, complied with
protocol procedures, and had antibody assay results
available. Cellular immunogenicity analyses were per-
formed on the month 12 ATP persistence cohort for
the month 12 timepoint and on the month 24 ATP
persistence cohort for the month 24 timepoint. A sub-
set of participants was randomly selected from each
adjuvanted vaccine group for measurement of neutra-
lising antibodies.
Analyses were performed using SAS 9.1 (SAS Institute
Inc., Cary, NC, USA). Proc StatXact 5.0 (Cytel Inc.,
Cambridge, MA, USA) was used to calculate 95% CIs
for GMT, SCR and SPR. The immunogenicity results for
the follow-up study phases were reported descriptively.
Results
A total of 345 and 320 participants were enrolled in, and
completed, the month 12 and month 24 follow-up
phases of the study, respectively. The month 12 and
month 24 ATP persistence cohorts included 298 and
228 participants, respectively (Figure 1A,B).
Demographic characteristics were similar across the
study groups. In the ATP cohort for persistence at
month 24, the overall mean age (± standard deviation)
of participants at the time of first vaccination was 68.7 ±
6.18 years (range 61 to 89 years); 46.5% of participants
were women, and the majority (95.2%) were of Cauca-
sian/European heritage (Table 1).
Haemagglutination inhibition antibody response
At month 12, the percentages of participants who remained
seropositive for HI antibodies against A/Vietnam/1194/
2004 were 62.8% (95% CI 51.7% to 73.0%) and 77.8% (95%
CI 67.2% to 86.3%) in the adjuvanted 1xH5N1-AS and
2xH5N1-AS groups, respectively, compared to 48.6% (95%
Figure 1 Participant flow diagram. Vaccination groups are: 1xH5N1-AS, single dose of the AS03A-adjuvanted vaccine; 1xH5N1, single dose of the
non-adjuvanted vaccine; 2xH5N1-AS, double dose of the AS03A-adjuvanted vaccine; 2xH5N1, double dose of the non-adjuvanted vaccine. ATP,
according-to-protocol; M, month; N, number of participants in the specified group; n, number of participants with the specified reason for elimination.
Table 1 Demographic characteristics of the participants (month 24 according-to-protocol persistence cohort)
1xH5N1-AS 1xH5N1 2xH5N1-AS 2xH5N1 Total
N = 86 N = 37 N = 81 N = 24 N = 228
Age Mean ± SD 68.5 ± 6.32 68.6 ± 5.15 69.2 ± 6.48 67.7 ± 6.30 68.7 ± 6.18
Range (min–max) 61–85 61–81 61–89 61–85 61–89
Gender: n (%) Female 42 (48.8) 15 (40.5) 39 (48.1) 10 (41.7) 106 (46.5)
Race: n (%) White-Caucasian/European heritage 85 (98.8) 36 (97.3) 74 (91.4) 22 (91.7) 217 (95.2)
White-Arabic/North African heritage 1 (1.2) 1 (2.7) 7 (8.6) 2 (8.3) 11 (4.8)
N, number of participants in the specified group; n (%), number of participants with the specified characteristic; SD, standard deviation. Vaccination groups are:
1xH5N1-AS, single dose of the AS03A-adjuvanted vaccine; 1xH5N1, single dose of the non-adjuvanted vaccine; 2xH5N1-AS, double dose of the AS03A-adjuvanted
vaccine; 2xH5N1, double dose of the non-adjuvanted vaccine.
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the non-adjuvanted 1xH5N1 and 2xH5N1 groups, respect-
ively. At month 24, seropositivity rates were in a similar
range to those at month 12; 62.8% (95% CI 51.7% to
73.0%) in the 1xH5N1-AS group, 70.4% (95% CI 59.2%
to 80.0%) in the 2xH5N1-AS group, 54.1% (95% CI
36.9% to 70.5%) in the non-adjuvanted 1xH5N1 group,
and 45.8% (95% CI 25.6% to 67.2%) in the non-
adjuvanted 2xH5N1 group.
GMTs for HI antibodies against A/Vietnam/1194/2004
waned considerably as time elapsed after the last pri-
mary dose. At month 12, HI antibody GMTs were 22.2
(95% CI 16.5 to 29.9) in the 1xH5N1-AS group, 25.7Figure 2 H5N1 haemagglutination inhibition antibody response again
dose of the AS03A-adjuvanted vaccine; 1xH5N1, single dose of the non-adj
vaccine; 2xH5N1, double dose of the non-adjuvanted vaccine. Seroconvers
a pre-vaccination titre <1:10 and a post-vaccination titre ≥1:40, or a pre-vac
seroprotection rate (SPR) was defined as the percentage of participants wit
titre. Error bars indicate the 95% confidence intervals. Post-vaccination = da
the according-to-protocol immunogenicity cohort (1xH5N1-AS: N =152, 1xH
month 24 results for the month 24 according-to-protocol persistence coho
N = 24); N =maximum number of participants with available results.(95% CI 19.3 to 34.3) in the 2xH5N1-AS group, 13.6
(95% CI 8.9 to 20.8) in the 1xH5N1 group and 10.0 (95%
CI 6.5 to 15.5) in the 2xH5N1 group (Figure 2A). At
month 24, GMTs were 17.6 (95% CI 13.7 to 22.5) for
1xH5N1-AS, 18.4 (95% CI 14.2 to 23.8) for 2xH5N1-AS,
12.3 (95% CI 8.9 to 16.9) for 1xH5N1 and 9.8 (95% CI
6.7 to 14.4) for 2xH5N1 (Figure 2A). In comparison,
pre-vaccination GMTs were 11.5 (95% CI 8.7 to 15.1) for
1xH5N1-AS, 9.7 (95% CI 7.4 to 12.5) for 2xH5N1-AS,
9.3 (95% CI 6.3 to 13.6) for 1xH5N1 and 6.8 (95% CI 5.4
to 8.7) for 2xH5N1.
For SCR and SPR, CHMP criteria were no longer
fulfilled at both month 12 and month 24 for the HIst A/Vietnam/1194/2004. Vaccination groups are: 1xH5N1-AS, single
uvanted vaccine; 2xH5N1-AS, double dose of the AS03A-adjuvanted
ion rate (SCR) was defined as the percentage of participants with either
cination titre ≥1:10 and a ≥4-fold increase in post-vaccination titre; and
h a haemagglutination inhibition titre ≥1:40. GMT, geometric mean
y 42 (data also shown in [13]). Post-vaccination results are shown for
5N1: N =54, 2xH5N1-AS: N =145, 2xH5N1: N = 44); month 12 and
rt (1xH5N1-AS: N = 86, 1xH5N1: N = 37, 2xH5N1-AS: N =81, 2xH5N1:
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(Figure 2B,C and Figure 3B,C). At month 24, HI anti-
body seroprotection rates were 37.2% (95% CI 27.0% to
48.3%) in the 1xH5N1-AS group, 30.9% (95% CI 21.1%
to 42.1%) in the 2xH5N1-AS group, 16.2% (95% CI 6.2%
to 32.0%) in the non-adjuvanted 1xH5N1 group, and
8.3% (95% CI 1.0% to 27.0%) in the non-adjuvanted
2xH5N1 group.
The heterologous HI immune response against the A/
Indonesia/05/2005 strain was lower than against the A/
Vietnam/1194/2004 strain in all groups (Figure 3A-C),
with a GMT of 7.0 (95% CI 6.1 to 8.1) for 1xH5N1-AS,
7.3 (95% CI 6.2 to 8.6) for 2xH5N1-AS, 5.6 (95% CI 4.9Figure 3 H5N1 haemagglutination inhibition antibody response again
groups are: 1xH5N1-AS, single dose of the AS03A-adjuvanted vaccine; 1xH5
dose of the AS03A-adjuvanted vaccine; 2xH5N1, double dose of the non-ad
percentage of participants with either a pre-vaccination titre <1:10 and a p
increase in post-vaccination titre; and seroprotection rate (SPR) was defined
titre ≥1:40. GMT, geometric mean titre. Error bars indicate the 95% confiden
shown for the according-to-protocol immunogenicity cohort (1xH5N1-AS:
12 and month 24 results for the month 24 according-to-protocol persisten
2xH5N1: N =24); N =maximum number of participants with available resultto 6.4) for 1xH5N1 and 5.0 (95% CI 5.0 to 5.0) for
2xH5N1 at month 24; these values were below the cut-
off of 10. GMTs remained higher than baseline for the
adjuvanted groups while those of the non-adjuvanted
groups were in the same range as baseline values; pre-
vaccination GMTs were 5.1 (95% CI 5.0 to 5.2) for
1xH5N1-AS, 5.1 (95% CI 5.0 to 5.3) for 2xH5N1-AS, 5.1
(95% CI 4.9 to 5.3) for 1xH5N1, and 5.0 (95% CI 5.0 to
5.0) for 2xH5N1.
Neutralising antibody response
All participants in the adjuvanted groups remained sero-
positive for neutralising antibodies against A/Vietnam/st the heterologous A/Indonesia/05/2005 strain. Vaccination
N1, single dose of the non-adjuvanted vaccine; 2xH5N1-AS, double
juvanted vaccine. Seroconversion rate (SCR) was defined as the
ost-vaccination titre ≥1:40, or a pre-vaccination titre ≥1:10 and a ≥4-fold
as the percentage of participants with a haemagglutination inhibition
ce intervals. Post-vaccination = day 42. Post-vaccination results are
N =152, 1xH5N1: N = 54, 2xH5N1-AS: N = 145, 2xH5N1: N = 44); month
ce cohort (1xH5N1-AS: N = 86, 1xH5N1: N = 37, 2xH5N1-AS: N = 81,
s.
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decrease in antibody GMTs and SCRs compared to
3 weeks post-vaccination (Figure 4A,B). The antibody
GMTs remained higher than the pre-vaccination values,
which were 131.8 (95% CI 95.4 to 182.1) for the 1xH5N1-
AS group and 115.6 (95% CI 90.0 to 148.4) for the
2xH5N1-AS group.
Most participants (≥84.1%) remained seropositive
for neutralising antibodies against the heterologous A/
Indonesia/05/2005 strain, with a decrease in antibody
GMTs at both month 12 and month 24 (Figure 5).
Pre-vaccination GMTs were 50.4 (95% CI 38.6 to 65.8)
for 1xH5N1-AS and 36.6 (95% CI 27.8 to 48.1) for
2xH5N1-AS.Cell-mediated immunity
Antigen-specific CD4+ T-cell responses decreased be-
tween day 42 and month 12, and remained within a
similar range at month 24. At month 24, the median
frequency of antigen-specific CD4+ T cells per 106Figure 4 Neutralising antibody response against A/Vietnam/1194/2004
single dose of the AS03A-adjuvanted vaccine; 1xH5N1, single dose of the non
vaccine; 2xH5N1, double dose of the non-adjuvanted vaccine. Seroconversion
increase in neutralising antibody titre at post-vaccination. GMT, geometric mean
day 42 (data also shown in [13]). Post-vaccination results are shown for a subset
N =87, 2xH5N1-AS: N =82), month 12 and month 24 results for a subset of the
2xH5N1-AS: N =54); N =maximum number of participants with available resultsT cells (25th quartile; 75th quartile) was 852 (482;
1477) for 1xH5N1-AS, 1147 (662; 1698) for 2xH5N1-
AS, 556 (343; 749) for 1xH5N1 and 673 (465; 1497) for
2xH5N1 (Figure 6). No CD8+ T-cell responses were
observed.Safety
Between months 6 and 12, 12 non-fatal SAEs were re-
ported by 9 of 345 participants (2 in the 2xH5N1 group,
3 in the 2xH5N1-AS group and 4 in the 1xH5N1-AS
group). One SAE was considered causally related to vac-
cination by the investigator (right inferior lobar pneumo-
nia of undetermined cause, with onset 299 days after the
second dose in the 2xH5N1 group).
Between months 12 and 24, 29 non-fatal SAEs were
reported by 25 of 320 participants (2 in the 2xH5N1
group, 9 in the 1xH5N1-AS group and 7 each in
the 1xH5N1 and the 2xH5N1-AS group). None of
these SAEs were considered to be causally related to
vaccination.in the AS03A-adjuvanted groups. Vaccination groups are: 1xH5N1-AS,
-adjuvanted vaccine; 2xH5N1-AS, double dose of the AS03A-adjuvanted
rate (SCR) was defined as the percentage of vaccinees with a ≥4-fold
titre. Error bars indicate the 95% confidence intervals. Post-vaccination =
of the according-to-protocol immunogenicity cohort (1xH5N1-AS:
month 24 according-to-protocol persistence cohort (1xH5N1-AS: N =51,
.
Figure 5 Neutralising antibody response against the heterologous A/Indonesia/05/2005 strain in the AS03A-adjuvanted groups.
Vaccination groups are: 1xH5N1-AS, single dose of the AS03A-adjuvanted vaccine; 1xH5N1, single dose of the non-adjuvanted vaccine; 2xH5N1-AS,
double dose of the AS03A-adjuvanted vaccine; 2xH5N1, double dose of the non-adjuvanted vaccine. Seroconversion rate (SCR) was defined
as the percentage of vaccinees with a ≥4-fold increase in neutralising antibody titre at post-vaccination. GMT, geometric mean titre. Error bars
indicate the 95% confidence intervals. Post-vaccination = day 42. Post-vaccination results are shown for a subset of the according-to-protocol
immunogenicity cohort (1xH5N1-AS: N =87, 2xH5N1-AS: N =82), month 12 and month 24 results for a subset of the month 24 according-to-protocol
persistence cohort (1xH5N1-AS: N =51, 2xH5N1-AS: N =54); N =maximum number of participants with available results.
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Discussion
It is well established that the immune response to vac-
cination is weaker in older individuals [12]. We previ-
ously reported that two injections of a double dose of
the AS03A-adjuvanted H5N1 pandemic vaccine in-
duced a stronger immune response than two injec-
tions of a single dose in participants (>60 years old),
although administration of two single vaccine doses
was sufficient to meet the licensing criteria [13]. In
addition, we reported that HI and neutralizing anti-
bodies persisted at 6 months after vaccination with
the AS03A-adjuvanted H5N1 pandemic vaccine for-
mulations [13].
Here, we showed that persistence of the antibodies
was observed up to 2 years after vaccination, although
expectedly antibody GMTs decreased considerably
over time. Two double-dose vaccinations had no effect
on the persistence of the immune response comparedto two single-dose injections. This, together with our
previous finding that the single-dose regimen was
sufficient to meet licensing criteria, further supports
the use of the registered adult dose and schedule in
the elderly population. This knowledge is valuable in
terms of simplification of the vaccination schedule
across adulthood with no need for a specific dosage
for elderly individuals, and it reduces the strain on the
limited global production capacity of influenza antigen
in case of a pandemic. A similar pattern in adults and
elderly (≥61 years) has also been described for two
doses of an MF59-adjuvanted H5N1 pre-pandemic
vaccine [16]. Two doses of another AS03A-adjuvanted
H5N1 vaccine were also sufficient to meet licensing
criteria in older persons (≥65 years), although GMTs
were lower than in younger adults; persistence of the
antibody response was observed up to 182 days after
the first dose in both age groups [17].
Higher HI antibody levels were observed in the adju-
vanted vaccine groups than in the non-adjuvanted
Figure 6 CD4+ T cells specific for A/Vietnam/1194/2004 split-virus antigen, positive for ≥2 immunological markers. Antigen-specific
CD4+ T cells expressing ≥2 of the following immunological markers: CD40L, interleukin-2, tumour necrosis factor alpha, or interferon-gamma.
Line inside the box, median value; top line of box, third quartile; bottom line of box, first quartile; lower limit of error bar, minimum value; upper
limit of error bar, maximum value. Vaccination groups are: 1xH5N1-AS, single dose of the AS03A-adjuvanted vaccine; 1xH5N1, single dose of
the non-adjuvanted vaccine; 2xH5N1-AS, double dose of the AS03A-adjuvanted vaccine; 2xH5N1, double dose of the non-adjuvanted vaccine.
Post-vaccination = day 42 (data also shown in [13]). Post-vaccination results are shown for the according-to-protocol immunogenicity cohort
(1xH5N1-AS: N =120, 1xH5N1: N =43, 2xH5N1-AS: N =118, 2xH5N1: N =30), month 12 results for the month 12 according-to-protocol persistence
cohort (1xH5N1-AS: N =90, 1xH5N1: N =41, 2xH5N1-AS: N =91, 2xH5N1: N =30) and month 24 results for the month 24 according-to-protocol
persistence cohort (1xH5N1-AS: N =73, 1xH5N1: N =34, 2xH5N1-AS: N =72, 2xH5N1: N =22); N = number of participants with available results.
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were low. Addition of the AS03A adjuvant thus appears
to improve persistence of the immune response.
The observed neutralizing antibody titres for the vac-
cine homologous strain tended to be higher at month 24
than at month 12. However, this may most likely be ex-
plained by variability between assay runs, as the overall
GMT values were low.
The HI immune response against the heterologous A/
Indonesia/05/2005 strain was lower than against the A/
Vietnam/1194/2004 strain in all groups, and GMTs were
below the assay cut-off of 10 except for the 2xH5N1-AS
group at month 12. Neutralizing antibody GMTs against
A/Indonesia/05/2005 decreased compared to the post-
vaccination timepoint, but remained well above the assay
cut-off and also tended to be higher than the pre-
vaccination GMTs (although the 95% CIs were overlap-
ping for the 1xH5N1-AS group).
The use of antibody titres as a sole indicator for influ-
enza vaccine efficacy is of limited value in older people;
indeed, available data suggest that the cell-mediated im-
mune response should also be taken into account in the
evaluation of vaccine efficacy in this population [18-21].
T helper 1-cell frequencies have been shown to be a
good early predictor of seroprotection after booster vac-
cination [22]. Similarly, we previously observed higher
CD4+ T-cell responses against the A/Vietnam/1194/
2004 strain for the adjuvanted than non-adjuvanted
groups at day 21, which corresponded to higher post-dose two seroprotection rates in the adjuvanted groups
[13]. Our current results indicated similar patterns of
persistence of HI antibodies, neutralising antibodies,
and CD4+ T-cell responses, with a trend for improved
persistence of the cell-mediated immune response in
the adjuvanted vaccine groups. No CD8+ T-cell re-
sponses were observed, in line with our previous ob-
servations [13].
No assessment of memory B-cell response was per-
formed in the current study. However, in a long-term
booster study with AS03A-adjuvanted H5N1 vaccine
performed in a younger adult population from Asia, the
significant responses observed after one dose of heterol-
ogous booster vaccine up to 3 years after priming allow
to infer that a memory response is induced [23].
Conclusions
During the 2-year follow-up period, antibody levels de-
clined substantially in all groups. Higher GMTs for HI
antibodies were observed in the adjuvanted vaccine
groups compared to the non-adjuvanted vaccine groups.
The CD4+ T-cell responses also appeared higher in the
adjuvanted groups at both month 12 and month 24. This
study, together with the results from the preceding
study, therefore supports the suitability of the adult dos-
age and schedule of the AS03A-adjuvanted H5N1 pan-
demic vaccine for elderly persons.
No safety concern was observed up to 24 months after
primary vaccination.
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